Equine Precision Therapy: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Equine Precision Therapy
Largest movements
- Current investments +€74,910
new in 2025: €74,910
- Cash +€74,863
up €74,863 (+59.4%), from €126,077 to €200,940
mainly Accrued charges and deferred income (+€117,250) and Net result for the year (+€98,879)
- Deferred charges and accrued income +€73,994
up €73,994 (+17722.6%), from €418 to €74,411
- Receivables within one year +€18,312
up €18,312 (+51.1%), from €35,830 to €54,142
of which Other amounts receivable: +€20,945
- Accrued charges and deferred income +€117,250
new in 2025: €117,250
- Profit (loss) carried forward +€98,879
up €98,879 (+136.2%), from €72,585 to €171,464
- Tax, wage and social debts +€30,338
up €30,338 (+92.9%), from €32,659 to €62,997
- Gross operating margin +€40,248
up €40,248 (+39.3%), from €102,452 to €142,700
- Taxes +€7,686
up €7,686 (+35.3%), from €21,763 to €29,449
- Depreciation +€6,328
up €6,328 (+99.4%), from €6,366 to €12,694
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €171,751 | €413,138 | +€241,387 | +140.5% |
| Fixed assets | 21/28 | €9,426 | €8,733 | -€692 | -7.3% |
| Tangible fixed assets | 22/27 | €9,426 | €8,733 | -€692 | -7.3% |
| Plant, machinery and equipment | 23 | €885 | €524 | -€362 | -40.8% |
| Furniture and vehicles | 24 | €8,540 | €8,209 | -€331 | -3.9% |
| Current assets | 29/58 | €162,325 | €404,404 | +€242,079 | +149.1% |
| Stocks and contracts in progress | 3 | - | €1 | +€1 | |
| Stocks | 30/36 | - | €1 | +€1 | |
| Amounts receivable within one year | 40/41 | €35,830 | €54,142 | +€18,312 | +51.1% |
| Trade receivables | 40 | €35,830 | €33,197 | -€2,633 | -7.3% |
| Other amounts receivable | 41 | - | €20,945 | +€20,945 | |
| Current investments | 50/53 | - | €74,910 | +€74,910 | |
| Cash at bank and in hand | 54/58 | €126,077 | €200,940 | +€74,863 | +59.4% |
| Deferred charges and accrued income | 490/1 | €418 | €74,411 | +€73,994 | +17722.6% |
| Total equity and liabilities | 10/49 | €171,751 | €413,138 | +€241,387 | +140.5% |
| Equity | 10/15 | €123,788 | €222,668 | +€98,879 | +79.9% |
| Contributions | 10/11 | €2,000 | €2,000 | = | 0.0% |
| Reserves | 13 | €49,204 | €49,204 | = | 0.0% |
| Distributable reserves | 133 | €49,204 | €49,204 | = | 0.0% |
| Profit (loss) carried forward | 14 | €72,585 | €171,464 | +€98,879 | +136.2% |
| Amounts payable | 17/49 | €47,963 | €190,470 | +€142,507 | +297.1% |
| Amounts payable within one year | 42/48 | €47,963 | €73,220 | +€25,257 | +52.7% |
| Trade debts | 44 | €12,391 | €10,223 | -€2,168 | -17.5% |
| Suppliers | 440/4 | €12,391 | €10,223 | -€2,168 | -17.5% |
| Taxes, remuneration and social security | 45 | €32,659 | €62,997 | +€30,338 | +92.9% |
| Taxes | 450/3 | €32,659 | €62,997 | +€30,338 | +92.9% |
| Other amounts payable | 47/48 | €2,913 | - | -€2,913 | |
| Accrued charges and deferred income | 492/3 | - | €117,250 | +€117,250 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €6,366 | €12,694 | +€6,328 | +99.4% |
| Gross operating margin | 9900 | €102,452 | €142,700 | +€40,248 | +39.3% |
| Operating profit (loss) | 9901 | €96,086 | €130,006 | +€33,919 | +35.3% |
| Financial income | 75/76B | €1 | €355 | +€354 | +26614.3% |
| Recurring financial income | 75 | €1 | €355 | +€354 | +26614.3% |
| Financial charges | 65/66B | €1,740 | €2,032 | +€293 | +16.8% |
| Recurring financial charges | 65 | €1,740 | €2,032 | +€293 | +16.8% |
| Profit (loss) for the period before taxes | 9903 | €94,348 | €128,329 | +€33,981 | +36.0% |
| Income taxes | 67/77 | €21,763 | €29,449 | +€7,686 | +35.3% |
| Profit (loss) for the period | 9904 | €72,585 | €98,879 | +€26,295 | +36.2% |
| Profit (loss) for the period to be appropriated | 9905 | €72,585 | €98,879 | +€26,295 | +36.2% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.